Table 2 Data collection methods, timing, and measures

 Pre-site visit phone interviews—once at baseline

Organizational structure, key stakeholders, practice champion

Approaches to delivery of adolescent preventive care services (such as immunizations)

 Formal site visit—once at baseline

Baseline workflows; baseline patient data collection: eligible patient population, patient demographics, and other characteristics of the patient population; baseline immunization rates; baseline community partnership data: existing education programs and efforts and existing partnerships; use of ALERT IIS and EHR to capture and track immunizations

 Practice survey (PS)—once at baseline

Practice and practice’s patient demographics, practice change, payer mix, revenue and payments, and HPV vaccine priority

 ALERT IIS—at baseline

Patient demographics (age, race/ethnicity, vaccination status, insurance status, and other covariates)

 Quality Improvement Change Questionnaire (QICA)—every 12 months

Engaged leadership

Organized, evidence-based care; quality improvement strategy; continuous and team-based healing relationships; care coordination

 Site visits—monthly, for 18 months

Workflows; patient data collection: eligible patient population, patient demographics, and other characteristics of the patient population; quarterly immunization rates; quarterly community partnership data: existing education programs and efforts; existing partnerships

 Intervention data entries—monthly

PDSA cycle worksheets, workflow mapping, field notes

 Practice survey (PS), administered as needed to reflect change

Practice and practice’s patient demographics, practice change, payer mix, revenue and payments, HPV vaccine priority

 ALERT IIS—quarterly

Patient demographics (age, race/ethnicity, vaccination status, insurance status, and other covariates)

 Pre- and post-community partner group interviews

Acceptability of HPV vaccination

 Patient/parent surveys—every 6 months

Child and parents’ knowledge about cancer risk reduction and the HPV vaccine series; where and how information about HPV and cancer risk reduction via vaccination was sought; demographic information